Advertisement: TTP Killer 50
27 March, 2019 - 15:12 By Kate Sweeney

Cambridge Cancer Genomics

John Cassidy Cambridge Cancer Genomics

The health technology company is building tools to enable oncologists to make the best therapeutic decisions for their patients.

Cambridge Cancer Genomics is backed by Y Combinator, the California seed accelerator, incorporated in the UK and anchored in Cambridge. It also has a key alliance with the globally respected Comprehensive Blood & Cancer Centre in Bakersfield, California among other partnerships on both sides of the Pond.

The company is soon to embark on a fresh round of fundraising to fuel its R & D activities. CCG is reluctant to forecast exact figures but, assessing the traction already secured by the startup and its transatlantic potential, it could raise anything between $20m and $50m. 

It has already raised around $4.5m seed capital, Business Weekly understands.

Newsletter Subscription

Stay informed of the latest news and features